NasdaqGM - Nasdaq Real Time Price ? USD Aquestive Therapeutics, Inc. (AQST) Follow Compare 4.9500 -0.0800 (-1.59%) At close: October 21 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2024 and provide an update on recent developments in its business after market close on Monday, November 4, 2024. Management will host a con GlobeNewswire ? 22 hours ago AQST -1.59% Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate On Friday, Aquestive Therapeutics, Inc. (NASDAQ:AQST) hosted a virtual investor day highlighting the company’s Anaphylm (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel. Aquestive said it completed enrollment in its remaining supportive study for Anaphylm, the oral allergy syndrome (OAS) challenge study. Following the completion of dosing, the study is expected to be completed in the fourth quarter of 2024. The company remains on track to hold the FDA pre-New Drug Application Benzinga ? 21 days ago AQST -1.59% Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm? (epinephrine) Sublingual FilmOutlines the development strategy for the Company’s next pipeline product candidate, AQST-108 (epinephrine) Topical Gel for the treatment of Alopecia areataHolds virtual investor day WARREN, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company GlobeNewswire ? 24 days ago AQST -1.59% Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th WARREN, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced it will hold a virtual investor day on September 27, 2024 at 8:00 am ET to discuss the Company’s pipeline updates, inclusive of Anaphylm? (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel, b GlobeNewswire ? last month AQST -1.59% Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in September 2024 as follows: H.C. Wainwright 26th Annual Global Investor Conference: presentation at 8:30 am ET on Monday, Septemb GlobeNewswire ? last month AQST -1.59% Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm? Applauds first FDA approval of non-injection-based epinephrine deviceReiterates expected timing for filing of New Drug Application (NDA) for Anaphylm? (epinephrine) Sublingual Film to the FDA in the first quarter of 2025 WARREN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today GlobeNewswire ? 2 months ago AQST -1.59% Aquestive Therapeutics Second Quarter 2024 Earnings: Beats Expectations Aquestive Therapeutics ( NASDAQ:AQST ) Second Quarter 2024 Results Key Financial Results Revenue: US$20.1m (up 52% from... Simply Wall St. ? 2 months ago AQST -1.59% Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Zacks ? 2 months ago AQST -1.59% Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 72.73% and 59.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 2 months ago AQST -1.59% Aquestive Therapeutics: Q2 Earnings Snapshot The Warren, New Jersey-based company said it had a loss of 3 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 11 cents per share. Associated Press Finance ? 2 months ago AQST -1.59% Aquestive Therapeutics Reports Second Quarter 2024 Financial Results?and Provides Business Update Late-stage pipeline program, Anaphylm? (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDAExpanded sales coverage for Libervant? (diazepam) Buccal Film for patients between ages two to five with national retail distribution anticipated in the fourth quarter 2024Anticipates holding epinephrine prodrug technology investor day in the coming monthsFinishes the second quarter 2024 with cash and cash equivalents of approximately $90 million GlobeNewswire ? 2 months ago AQST -1.59% Institutions profited after Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) market cap rose US$72m last week but retail investors profited the most Key Insights Aquestive Therapeutics' significant retail investors ownership suggests that the key decisions are... Simply Wall St. ? 2 months ago AQST -1.59% Aquestive Therapeutics Reports Positive Topline Data for Anaphylm? (epinephrine) Sublingual Film from Self-Administration Study Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs)Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pre-New Drug Application (NDA) meeting before the end of the third quarter WARREN, N.J., July 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company GlobeNewswire ? 2 months ago AQST -1.59% Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2024 and provide an update on recent developments in its business after market close on Tuesday, August 6, 2024. Management will host a conferen GlobeNewswire ? 2 months ago AQST -1.59% New Strong Sell Stocks for July 11th AQST, CENTA and RAMP have been added to the Zacks Rank #5 (Strong Sell) List on July 11, 2024. Zacks ? 3 months ago AQST -1.59% RAMP Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024. The forum will include panels exploring key therape GlobeNewswire ? 3 months ago AQST -1.59% Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows On Tuesday, Aquestive Therapeutics Inc (NASDAQ:AQST) released topline pharmacokinetic (PK) data from the temperature / pH study of its product candidate Anaphylm (epinephrine) Sublingual Film. Anaphylm is the company’s first and only orally administered epinephrine prodrug product candidate under development for severe life-threatening allergic reactions, including anaphylaxis. In March, Aquestive Therapeutics released topline clinical data from its Phase 3 PK study of Anaphylm, meeting all prim Benzinga ? 3 months ago AQST -1.59% Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm? (epinephrine) Sublingual Film Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pHRemains on track to complete Anaphylm supportive clinical studies and expects to request pre-NDA meeting with FDA in the third quarter 2024Continues to anticipate filing a New Drug Application (NDA) shortly after completion of its pediatric study of Anaphylm WARREN, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a phar GlobeNewswire ? 3 months ago AQST -1.59% Investors in Aquestive Therapeutics (NASDAQ:AQST) have unfortunately lost 36% over the last five years Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more... Simply Wall St. ? 4 months ago AQST -1.59% Aquestive Therapeutics to Join the Russell 3000? and Russell 2000? Indexes Effective June 28, 2024 WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000? and Russell 2000? Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday GlobeNewswire ? 4 months ago AQST -1.59% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return AQST S&P 500 YTD +145.05% +22.73% 1-Year +221.43% +38.58% 3-Year +12.76% +29.05%
